The liminal space of first-episode psychosis and its treatment: A qualitative study exploring the experience of young people participating in an antipsychotic dose reduction randomized controlled trial.
- 1 December 2024
- journal article
- research article
- Published by American Psychological Association (APA) in Psychiatric Rehabilitation Journal
- Vol. 47 (4) , 313-321
Abstract
The current guidelines recommend continuation of antipsychotic medication for a minimum of at least 1 year following a first episode of psychosis (FEP). There have been several trials investigating whether early dose reduction or cessation leads to improved functional outcomes. The aim of this study was to explore the experience of consenting to and participating in a randomized controlled trial (RCT) of antipsychotic medication cessation. Five participants in the Reduce trial-an RCT evaluating early antipsychotic medication dose reduction/cessation following FEP-aged 22-24 years completed a semistructured qualitative interview following the RCT. Interpretive phenomenological analysis was undertaken to understand the key themes. A superordinate theme was derived from interviews: the Liminal Space of FEP and treatment. Themes within the Liminal Space included: rejection versus identification with psychosis, medication as symbolic of illness versus wellness, embodiment of wellness and illness with medication, medication as symbolic of independence versus dependence, discovery of independence when autonomously choosing medication, the Reduce trial offered safety to navigate the liminal space, and self-exploration versus altruism. The experience and treatment of FEP involves young people feeling torn between multiple, competing perspectives, demands, and priorities. Participation in an RCT exploring dose reduction provided additional supports contributing to the perception of greater safety to navigate their own experiences of treatment that was appropriate for them. When treatment is experienced as collaborative, involves shared decision making and support, other than medication, young people feel more equipped to navigate the liminal space. (PsycInfo Database Record (c) 2024 APA, all rights reserved).Keywords
This publication has 29 references indexed in Scilit:
- Experiences of reduction and discontinuation of antipsychotics: a qualitative investigation within the RADAR trialeClinicalMedicine, 2023
- The lived experience of psychosis: a bottom‐up review co‐written by experts by experience and academicsWorld Psychiatry, 2022
- Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable SchizophreniaJAMA Psychiatry, 2021
- Experiences of taking neuroleptic medication and impacts on symptoms, sense of self and agency: a systematic review and thematic synthesis of qualitative dataSocial Psychiatry and Psychiatric Epidemiology, 2019
- Non-adherence to pharmacological treatment in schizophrenia and schizophrenia spectrum disorders – An updated systematic literature reviewThe European Journal of Psychiatry, 2017
- Much ado about everything: A literature review of insight in first episode psychosis and schizophreniaEuropean Psychiatry, 2017
- Self‐Compassion and Self‐Criticism in Recovery in Psychosis: An Interpretative Phenomenological Analysis StudyJournal of Clinical Psychology, 2015
- Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment StrategyJAMA Psychiatry, 2013
- Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysisThe Lancet, 2012
- A prospective evaluation of adherence to medication in first episode schizophreniaEuropean Psychiatry, 2006